Brief isoflurane anesthesia regulates striatal AKT-GSK3 beta signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease

Show full item record



Permalink

http://hdl.handle.net/10138/248407

Citation

Leikas , J V , Kohtala , S , Theilmann , W , Jalkanen , A J , Forsberg , M M & Rantamaki , T 2017 , ' Brief isoflurane anesthesia regulates striatal AKT-GSK3 beta signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease ' , Journal of Neurochemistry , vol. 142 , no. 3 , pp. 456-463 . https://doi.org/10.1111/jnc.14066

Title: Brief isoflurane anesthesia regulates striatal AKT-GSK3 beta signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease
Author: Leikas, Juuso V.; Kohtala, Samuel; Theilmann, Wiebke; Jalkanen, Aaro J.; Forsberg, Markus M.; Rantamaki, Tomi
Other contributor: University of Helsinki, Biosciences
University of Helsinki, Biosciences
University of Helsinki, Biosciences

Date: 2017-08
Language: eng
Number of pages: 8
Belongs to series: Journal of Neurochemistry
ISSN: 0022-3042
DOI: https://doi.org/10.1111/jnc.14066
URI: http://hdl.handle.net/10138/248407
Abstract: Parkinson's disease (PD) is a progressive neurodegenerative movement disorder primarily affecting the nigrostriatal dopaminergic system. The link between heightened activity of glycogen synthase kinase 3 beta (GSK313) and neurodegenerative processes has encouraged investigation into the potential disease-modifying effects of novel GSK3 beta inhibitors in experimental models of PD. Therefore, the intriguing ability of several anesthetics to readily inhibit GSK3 beta within the cortex and hippocampus led us to investigate the effects of brief isoflurane anesthesia on striatal GSK3 beta signaling in nave rats and in a rat model of early-stage PD. Deep but brief (20-min) isoflurane anesthesia exposure increased the phosphorylation of GSK3 beta at the inhibitory Ser9 residue, and induced phosphorylation of AKT(Thr308) (protein kinase B; negative regulator of GSK3 beta) in the striatum of naive rats and rats with unilateral striatal 6-hydroxydopamine (6-OHDA) lesion. The 6-OHDA protocol produced gradual functional deficiency within the nigrostriatal pathway, reflected as a preference for using the limb ipsilateral to the lesioned striatum at 2 weeks post 6-OHDA. Interestingly, such motor impairment was not observed in animals exposed to four consecutive isoflurane treatments (20-min anesthesia every 48 h; treatments started 7 days after 6-OHDA delivery). However, isoflurane had no effect on striatal or nigral tyrosine hydroxylase (a marker of dopaminergic neurons) protein levels. This brief report provides promising results regarding the therapeutic potential and neurobiological mechanisms of anesthetics in experimental models of PD and guides development of novel disease-modifying therapies.
Subject: anesthesia
dopamine
neurodegeneration
phosphorylation
sensorimotor test
GLYCOGEN-SYNTHASE KINASE-3
ELECTROCONVULSIVE SHOCK
ALPHA-SYNUCLEIN
DOPAMINE
PHOSPHORYLATION
PATHWAY
BRAIN
NEUROPROTECTION
HIPPOCAMPUS
INHIBITION
1182 Biochemistry, cell and molecular biology
3112 Neurosciences
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Leikas_et_al_2017_Journal_of_Neurochemistry.pdf 722.2Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record